Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.

about

Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells.

P2860

Q47139100-60F32D55-590E-46B8-90B7-03944B0A6DE9

P2860

Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.

Item

http://www.wikidata.org/entity/Q39411920

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Mechanisms of Resistance to AB ...... eration ABL Kinase Inhibitors.

@en

Mechanisms of Resistance to AB ...... eration ABL Kinase Inhibitors.

@nl

type

Item

label

Mechanisms of Resistance to AB ...... eration ABL Kinase Inhibitors.

@en

Mechanisms of Resistance to AB ...... eration ABL Kinase Inhibitors.

@nl

prefLabel

Mechanisms of Resistance to AB ...... eration ABL Kinase Inhibitors.

@en

Mechanisms of Resistance to AB ...... eration ABL Kinase Inhibitors.

@nl

P1476

Mechanisms of Resistance to AB ...... eration ABL Kinase Inhibitors.

@en

P2093

Ami B Patel

http://www.w3.org/2001/XMLSchema#string

Michael W Deininger

http://www.w3.org/2001/XMLSchema#string

Thomas O'Hare

http://www.w3.org/2001/XMLSchema#string

P2860

Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance

Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells

Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells

P304

589-612

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.HOC.2017.04.007

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28673390

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

P932

5505321

http://www.w3.org/2001/XMLSchema#string

Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.

about

P2860

P2860

Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932